In brief: Gropep; Pharmaxis; Ventracor; Rockeby; Phosphagenics

By Renate Krelle
Tuesday, 23 November, 2004

Adelaide biotech GroPep (ASX:GRO) expects to deliver a net profit after tax of approximately $1 million for the six months to 31 December 2004 following sales growth of its cell culture products. Net profit for the full year 2004/05 is expected to be at least the $1.5 million.

Pharmaxis (ASX:PXS) has filed an Investigational New Drug (IND) application with the US Food and Drug Administration for the Phase III trial of its asthma diagnostic Aridol. The 130-person trial will be conducted over ten sites in the US.

Ventracor (ASX:VCR) expects to revisit its e-health roots, after a telemedicine patent retained from the 2003 sale if its e-health division was accepted by the US Patent and Trademark Office. The patent encompasses a system of connecting a medical device to a computer via an electronic communication network. CEO Colin Sutton said Ventracor anticipated incorporating telemedicine features into future versions of its VentrAssist device.

Rockeby Biomed (ASX:RBY) has appointed US-based biotech consultant Rich Casey as business development director and Nick Plumeridge as vice-president of marketing. Casey will take part in the selection a US marketing partner for the launch of Rockeby's thrush diagnostic CanDia5. Rockeby CEO Dr Sze Wee Tan said Rockeby intends to strike a marketing and distribution deal for CanDia5 in the US, and is already in talks with pharmaceutical and medical device companies in the women's health sector.

Phosphagenics (ASX:POH) has signed a material evaluation agreement with an undisclosed US-based pharmaceutical company under which the pharma will test the applicability of Phosphagenics' transdermal technology in its own patented system.

Related News

Indigenous-led initiative to resurrect the South Island Giant Moa

New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...

Abnormal brain protein targeted in Parkinson's study

Researchers have identified a new brain protein involved in the development of Parkinson's...

Epilepsy disease model treated in a laboratory dish

A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd